COMPANIES

No Data Found

NEWS

No Data Found
Metropolis Healthcare to open 25 labs, 500 centres in remote areas of North, East India

Metropolis Healthcare to open 25 labs, 500 centres in remote areas of North, East India

Company aims to reach 1,000 towns within the next 12 to 18 months.

Neetu Chandra Sharma
Neetu Chandra Sharma
  • Updated Oct 14, 2024 3:11 PM IST
Metropolis Healthcare to open 25 labs, 500 centres in remote areas of North, East IndiaIn the last financial year, Metropolis reported a total revenue of Rs 1,190 crore, reflecting a 3.6% year-on-year growth.

In a bid to reach underserved markets, Indian diagnostics chain Metropolis Healthcare is planning to enhance its presence across parts of North and East India by establishing 25 new laboratories and 500 centres in Tier III cities.

“We have expanded our footprint in Tier II and III cities, increasing our presence from 300 towns in FY23 to over 650 towns by Q1FY25. Revenue from Tier III cities has increased by 18% year-on-year, now accounting for more than 23% of our total revenue. We want to continue this momentum,” said Ameera Shah, Promoter and Executive Chairperson at Metropolis Healthcare.

Advertisement

This growth strategy aims to improve access to quality healthcare services in underserved areas. Currently, Metropolis operates 204 labs and 4,216 service centres in India and abroad. “This geographical expansion will enhance our accessibility and allow us to tap into growth potential,” Shah said.

The company aims to reach 1,000 towns within the next 12 to 18 months, and plans to increase its wellness segment from 16% to between 20% and 25% of overall business, while also boosting B2C offerings from 56% to 60-65%.

In the last financial year, Metropolis reported a total revenue of Rs 1,190 crore, reflecting a 3.6% year-on-year growth. Shah attributed this success to strategic enhancements in product mix and pricing, along with increased patient and test volumes. “Our digital revenue now accounts for 20% of our total revenue, showing our shift to digital healthcare solutions,” she said.

Advertisement

The wellness segment continues to grow, contributing 16% to total revenue, reflecting rising demand for preventive healthcare services. “We introduced 102 new tests in FY24, including AI-verified prostate biopsy tests and an expanded suite of Next Generation Sequencing (NGS) tests,” Shah stated. “These advancements reinforce our role in specialised diagnostics.”

Further, the company has diversified into basic radiology services, now available at 250 centres, with plans for further expansion. “This model integrates radiology into our existing network, enhancing customer value and ensuring operational efficiency,” she added.

Published on: Oct 14, 2024 3:11 PM IST
    Post a comment